Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Status:
Not yet recruiting
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in
postpartum (after childbirth) patients with benign breast disease planning to have a breast
biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer.
Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may
affect markers of inflammation in blood and tissue and may prevent postpartum related breast
cancer.